Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes

[1]  Daohong Zhou,et al.  Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. , 2020, European journal of medicinal chemistry.

[2]  Aditya R. Thawani,et al.  Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2 , 2020, Communications Biology.

[3]  B. Schulman,et al.  NEDD8 nucleates a multivalent cullin-RING-UBE2D ubiquitin ligation assembly , 2020, Nature.

[4]  Matthieu Schapira,et al.  Targeted protein degradation: expanding the toolbox , 2019, Nature Reviews Drug Discovery.

[5]  A. Ciulli,et al.  Structure‐Based Design of a Macrocyclic PROTAC , 2019, Angewandte Chemie.

[6]  William Farnaby,et al.  BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design , 2019, Nature Chemical Biology.

[7]  Asher Mullard,et al.  First targeted protein degrader hits the clinic , 2019, Nature Reviews Drug Discovery.

[8]  I. E. Smith,et al.  PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding. , 2019, ACS chemical biology.

[9]  Guangju Ji,et al.  A chemical approach for global protein knockdown from mice to non-human primates , 2019, Cell Discovery.

[10]  Michael L Drummond,et al.  In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application , 2019, J. Chem. Inf. Model..

[11]  M. Koegl,et al.  Crystal structure of human BRD9 bromodomain in complex with a PROTAC , 2019 .

[12]  M. Koegl,et al.  Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7 , 2018, Journal of medicinal chemistry.

[13]  Graham M. West,et al.  Delineating the role of cooperativity in the design of potent PROTACs for BTK , 2018, Proceedings of the National Academy of Sciences.

[14]  Hongying Gao,et al.  PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies , 2018, Cell Research.

[15]  J. Byrd,et al.  Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. , 2018, Biochemistry.

[16]  M. Naito,et al.  Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation , 2018, The Journal of Biological Chemistry.

[17]  James E. Bradner,et al.  Plasticity in binding confers selectivity in ligand induced protein degradation , 2018, Nature Chemical Biology.

[18]  Dennis L. Buckley,et al.  A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. , 2017, Cell chemical biology.

[19]  M. Naito,et al.  Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands , 2017, Cancer science.

[20]  G. Chessari,et al.  Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP). , 2017, Journal of medicinal chemistry.

[21]  Theresa Johnson,et al.  Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling , 2017, Molecular Pharmacology.

[22]  D. Lamont,et al.  Structural basis of PROTAC cooperative recognition for selective protein degradation , 2017, Nature chemical biology.

[23]  M. Naito,et al.  In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)* , 2017, The Journal of Biological Chemistry.

[24]  Jennifer L. Knight,et al.  OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. , 2016, Journal of chemical theory and computation.

[25]  G. Chessari,et al.  Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. , 2015, Journal of medicinal chemistry.

[26]  I. E. Smith,et al.  Catalytic in vivo protein knockdown by small-molecule PROTACs. , 2015, Nature chemical biology.

[27]  Dennis L. Buckley,et al.  Selective Target Protein Degradation via Phthalimide Conjugation , 2015 .

[28]  C. Crews,et al.  Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. , 2015, Chemistry & biology.

[29]  J. Byrd,et al.  Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.

[30]  Yigong Shi,et al.  Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. , 2014, Journal of medicinal chemistry.

[31]  Liu Liu,et al.  Potent and Selective Small-Molecule Inhibitors of cIAP1/2 Proteins Reveal That the Binding of Smac Mimetics to XIAP BIR3 Is Not Required for Their Effective Induction of Cell Death in Tumor Cells , 2014, ACS chemical biology.

[32]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[33]  Jeffrey A Jones,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[34]  M. Naito,et al.  Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy. , 2012, Bioorganic & medicinal chemistry letters.

[35]  Liu Liu,et al.  Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents. , 2012, Journal of medicinal chemistry.

[36]  Yukihiro Itoh,et al.  Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. , 2011, Bioorganic & medicinal chemistry.

[37]  S. Hymowitz,et al.  Antagonists Induce a Conformational Change in cIAP1 That Promotes Autoubiquitination , 2011, Science.

[38]  K. Wüthrich,et al.  Translational diffusion of macromolecular assemblies measured using transverse-relaxation-optimized pulsed field gradient NMR. , 2011, Journal of the American Chemical Society.

[39]  M. Hinds,et al.  CARD-mediated autoinhibition of cIAP1's E3 ligase activity suppresses cell proliferation and migration. , 2011, Molecular cell.

[40]  Yukihiro Itoh,et al.  Development of target protein-selective degradation inducer for protein knockdown. , 2011, Bioorganic & medicinal chemistry.

[41]  Yukihiro Itoh,et al.  Specific degradation of CRABP‐II via cIAP1‐mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein , 2011, FEBS letters.

[42]  D. Vaux,et al.  Smac Mimetics Activate the E3 Ligase Activity of cIAP1 Protein by Promoting RING Domain Dimerization* , 2011, The Journal of Biological Chemistry.

[43]  Su Qiu,et al.  Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. , 2010, Journal of medicinal chemistry.

[44]  Douglas H. Thamm,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.

[45]  Woody Sherman,et al.  ConfGen: A Conformational Search Method for Efficient Generation of Bioactive Conformers , 2010, J. Chem. Inf. Model..

[46]  Minoru Ishikawa,et al.  Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. , 2010, Journal of the American Chemical Society.

[47]  C. Crews,et al.  Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. , 2008, Bioorganic & medicinal chemistry letters.

[48]  Daniel C. Scott,et al.  Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation , 2008, Cell.

[49]  T. Tsuruo,et al.  Small Molecules Destabilize cIAP1 by Activating Auto-ubiquitylation* , 2008, Journal of Biological Chemistry.

[50]  Vishva M. Dixit,et al.  IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.

[51]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[52]  L. Honigberg,et al.  Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase , 2007, ChemMedChem.

[53]  G. Bricogne,et al.  Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. , 2004, Acta crystallographica. Section D, Biological crystallography.

[54]  M. Ivan,et al.  Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling , 2002, Science.

[55]  R. Deshaies,et al.  Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[56]  K Wüthrich,et al.  The program XEASY for computer-supported NMR spectral analysis of biological macromolecules , 1995, Journal of biomolecular NMR.

[57]  Ad Bax,et al.  Methodological advances in protein NMR , 1993 .

[58]  R. Keller.  Optimizing the process of nuclear magnetic resonance spectrum analysis and computer aided resonance assignment , 2005 .